Skip to main content

Drug Profiles/Updates

Drug Profiles/Updates, FDA Updates

Imbruvica (Ibrutinib) Now FDA Approved as First-Line Treatment for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Lisa A. Raedler, PhD, RPh, Medical Writer

Drug Profiles/Updates, FDA Updates

Lartruvo (Olaratumab) a Novel First-Line Treatment Approved for Patients with Advanced Soft-Tissue Sarcoma

Loretta Fala, Medical Writer

Drug Profiles/Updates, FDA Updates

Revlimid (Lenalidomide) Receives New Indication for Multiple Myeloma as Maintenance Therapy After Transplantation

Lisa A. Raedler, PhD, RPh, Medical Writer

Drug Profiles/Updates, FDA Updates

Rubraca (Rucaparib) Second PARP Inhibitor Approved for Patients with Advanced, BRCA-Positive Ovarian Cancer

Lisa A. Raedler, PhD, RPh, Medical Writer

Drug Profiles/Updates, FDA Updates

Tecentriq (Atezolizumab), PD-L1 Inhibitor, Approved for Advanced Bladder Cancer and for Relapsed Non–Small-Cell Lung Cancer

Lisa A. Raedler, PhD, RPh, Medical Writer

Drug Profiles/Updates, FDA Updates

Venclexta (Venetoclax) First BCL-2 Inhibitor Approved for High-Risk Relapsed Chronic Lymphocytic Leukemia

Lisa A. Raedler, PhD, RPh, Medical Writer

Drug Profiles/Updates

Venclexta (Venetoclax) First BCL-2 Inhibitor Approved for High-Risk Relapsed Chronic Lymphocytic Leukemia

Lisa A. Raedler, PhD, RPh, Medical Writer

Drug Profiles/Updates, FDA Updates

Keytruda (Pembrolizumab): First PD-1 Inhibitor Approved for the Treatment of Patients with Metastatic Non–Small-Cell Lung Cancer Expressing PD-L1

Lisa A. Raedler, PhD, RPh, Medical Writer

Drug Profiles/Updates, FDA Updates

Zarxio (Filgrastim-sndz): First Biosimilar Approved in the United States

Lisa A. Raedler, PhD, RPh, Medical Writer

Drug Profiles/Updates, FDA Updates

Varubi (Rolapitant) Approved for the Prevention of Delayed-Onset Chemotherapy-Induced Nausea and Vomiting

Lisa A. Raedler, PhD, RPh, Medical Writer

1
2
3
4

Page 2 of 4
Results 11 - 20 of 40